Buyback yield (TTM)
N/A
Shareholder yield (TTM)
N/A
5Y share count change
94.7%
Buyback spend (TTM)
N/A
Cumulative buybacks
$439.00K
Key takeaways
- Diluted share count is up 94.7% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM repurchases used about 0% of free cash flow remaining after dividends.
Dividend & buyback yield over time for Teladoc Health (TDOC)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Teladoc Health (TDOC)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Teladoc Health (TDOC)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Teladoc Health (TDOC)
Latest: $0.00
Overview
The 2025 reading of Teladoc Health (TDOC) buyback spend is $0.00.
Teladoc Health buyback spend plunged from $368.00K in 2014 to $0.00 in 2025, a 100.0% drawdown.
The record annual buyback spend stands at $368.00K, reached in 2014; the historical low of $0.00 was recorded in 2015.
Teladoc Health Buyback Spend 2025: $0.00
Teladoc Health buyback spend in 2025 was $0.00.
Teladoc Health Buyback Spend 2024: $0.00
Teladoc Health buyback spend in 2024 was $0.00.
Teladoc Health Buyback Spend 2023: $0.00
Teladoc Health buyback spend in 2023 was $0.00.
Teladoc Health Buyback Spend 2022: $0.00
Teladoc Health buyback spend in 2022 was $0.00.
Teladoc Health Buyback Spend 2021: $0.00
Teladoc Health buyback spend in 2021 was $0.00.
See more financial history for Teladoc Health (TDOC).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $0.00 | $80.41M | −$80.41M | — | 0.18B | +3.3% | |
| 2024 | $0.00 | $145.95M | −$145.95M | — | 0.17B | +3.6% | |
| 2023 | $0.00 | $201.55M | −$201.55M | — | 0.16B | +1.9% | |
| 2022 | $0.00 | $0.00 | $0.00 | — | 0.16B | +2.9% | |
| 2021 | $0.00 | $0.00 | $0.00 | — | 0.16B | +73.4% | |
| 2020 | $0.00 | $475.53M | −$475.53M | — | 0.09B | +26.0% | |
| 2019 | $0.00 | $66.70M | −$66.70M | — | 0.07B | +9.1% | |
| 2018 | $0.00 | $43.77M | −$43.77M | — | 0.07B | +18.8% | |
| 2017 | $0.00 | $30.60M | −$30.60M | — | 0.06B | +30.9% | |
| 2016 | $0.00 | $7.72M | −$7.72M | — | 0.04B | +112.5% | |
| 2015 | $0.00 | $3.08M | −$3.08M | — | 0.02B | -27.9% | |
| 2014 | $368.00K | $533.00K | −$165.00K | 0.07% | 0.03B | 0.0% | |
| 2013 | $71.00K | $298.00K | −$227.00K | — | 0.03B | — |
- 2025$0.00
- 2024$0.00
- 2023$0.00
- 2022$0.00
- 2021$0.00
- 2020$0.00
- 2019$0.00
- 2018$0.00
- 2017$0.00
- 2016$0.00
- 2015$0.00
- 2014$368.00K
- 2013$71.00K
Buybacks vs stock-based compensation for Teladoc Health (TDOC)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.00×.
Buybacks vs dividends (share of cash returned) for Teladoc Health (TDOC)
How Teladoc Health splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Teladoc Health, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $719.66M | |
| $216.35M | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $719.66M
- $216.35M
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $251.09M (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation